jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Eye tissue - Large Biopsy 3-6 cm

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Biopsy of ocular tissue.

₹666₹951

30% OFF

Eye Tissue - Large Biopsy 3-6 cm: Comprehensive Medical Test Information Guide

  • Why is it done?
    • Test Purpose: Large tissue biopsy (3-6 cm) obtained from ocular structures to provide definitive histopathological diagnosis of suspected eye diseases, tumors, or inflammatory conditions requiring substantial tissue sampling for comprehensive microscopic examination.
    • Primary Indications: Diagnosis of intraocular malignancies (retinoblastoma, uveal melanoma, lymphoma); evaluation of chronic ocular inflammation unresponsive to treatment; assessment of corneal scarring or dystrophy; diagnosis of conjunctival or episcleral lesions; investigation of suspicious orbital masses; confirmation of suspected infectious processes; characterization of eyelid or lacrimal gland tumors.
    • Typical Timing: Performed when other diagnostic modalities (imaging, ophthalmoscopy, ultrasound) demonstrate suspicious findings requiring tissue confirmation; typically conducted as an outpatient surgical procedure or in hospital operating room under local or general anesthesia depending on biopsy location and patient age.
  • Normal Range
    • Normal/Reference Findings: Histologically normal ocular tissue with intact epithelium, absence of malignant cells, no inflammatory infiltrates, normal vasculature, appropriate tissue architecture for the specific tissue origin (retinal, corneal, conjunctival, etc.), negative for infection, and absence of dysplastic changes.
    • Result Interpretation Categories: NEGATIVE/BENIGN - Normal tissue or benign pathology (inflammatory conditions, benign nevi, degenerative changes); POSITIVE/MALIGNANT - Confirmed malignancy with specific tumor type and grade; SUSPICIOUS/DYSPLASTIC - Abnormal tissue suggesting premalignant conditions requiring close monitoring or excision; INFLAMMATORY - Active inflammation consistent with specific conditions (sarcoidosis, tuberculosis, fungal infection); INCONCLUSIVE - Inadequate tissue or ambiguous findings requiring repeat biopsy.
    • Units of Measurement: Specimen size: 3-6 centimeters; Microscopic assessment: histopathological descriptors; Immunohistochemistry: percentage of positive cells; Flow cytometry (if applicable): percentage of cell populations; Molecular markers: present/absent or quantitative values.
    • Interpretation Framework: NORMAL indicates benign ocular pathology or absence of disease allowing conservative management; ABNORMAL findings indicating malignancy or significant pathology warrant immediate specialist consultation and treatment planning; SUSPICIOUS findings require correlation with clinical presentation and may necessitate additional diagnostic imaging or repeat sampling; results must be interpreted by ocular pathologist with appropriate clinical context.
  • Interpretation
    • Detailed Result Interpretation: Histopathological findings are analyzed by experienced ocular pathologists using light microscopy; electron microscopy or immunofluorescence may be employed for specific diagnoses; findings are classified according to WHO classification systems for ocular malignancies; tissue architecture, cellular morphology, mitotic rate, and nuclear features are documented.
    • Malignancy Indicators: Presence of atypical cells with high nuclear-to-cytoplasmic ratios; increased mitotic figures; evidence of invasion into normal tissue; tumor necrosis; vascular invasion; loss of normal tissue architecture; positive immunohistochemical markers specific to malignancy (CD20 for lymphoma, melanin for melanoma, etc.); genetic alterations or mutations specific to malignant conditions.
    • Inflammatory Findings: Dense lymphocytic or plasma cell infiltration; granuloma formation indicating chronic inflammation; identification of specific organisms (bacteria, fungi, parasites); presence of vasculitis; tissue edema; specific staining patterns (AFB for tuberculosis, GMS for fungi, special stains for organisms).
    • Infectious Agents: Identification through culture, PCR, or immunohistochemistry; Toxoplasma gondii; Mycobacterium tuberculosis; fungal species (Candida, Aspergillus, Cryptococcus); viral inclusions; parasitic organisms; bacteria including atypical organisms.
    • Factors Affecting Results: Specimen fixation and processing quality; tissue location and adequacy of sampling; prior radiation or chemotherapy effects; immunosuppression status; specimen handling and storage duration; crush artifact or thermal injury during collection; prior systemic medications affecting tissue appearance; presence of concurrent inflammation obscuring pathology.
    • Clinical Significance of Patterns: Benign findings allow surveillance or conservative management; localized malignancy may be amenable to local treatment; invasive malignancy suggests need for systemic therapy; high-grade lesions indicate aggressive disease requiring urgent intervention; inflammatory patterns direct antimicrobial or immunosuppressive therapy; dysplastic changes warrant close surveillance for transformation to malignancy.
  • Associated Organs
    • Primary Organ Systems: Eye (specifically retina, uvea, cornea, conjunctiva, sclera); eyelid structures; lacrimal gland system; optic nerve; orbital soft tissues; anterior segment tissues.
    • Conditions Diagnosed by Malignant Findings: Retinoblastoma (pediatric intraocular malignancy); Uveal melanoma (choroidal, ciliary body, iris melanomas); Intraocular lymphoma (primary vitreous lymphoma, secondary systemic lymphoma involvement); Metastatic tumors to eye/orbit; Conjunctival malignancies (squamous cell carcinoma, melanoma); Lacrimal gland tumors (adenoid cystic carcinoma, mucoepidermoid carcinoma); Eyelid malignancies (basal cell carcinoma, sebaceous gland carcinoma).
    • Associated Inflammatory Conditions: Tuberculous uveitis; Sarcoidosis with ocular involvement; Toxoplasma gondii chorioretinitis; Fungal infections (aspergillosis, candidiasis); Sympathetic ophthalmia; Behçet's disease; Tuberculosis; Syphilis; Cytomegalovirus retinitis; Acute retinal necrosis; Multifocal choroiditis.
    • Potential Complications of Abnormal Results: Vision loss or blindness from tumor progression; metastatic disease dissemination; loss of eye requiring enucleation; orbital cellulitis from infectious processes; secondary glaucoma; retinal detachment; vitreous hemorrhage; phthisis bulbi from chronic inflammation; systemic dissemination of malignancy; treatment-related complications (radiation retinopathy, chemotherapy toxicity).
    • Related Systemic Manifestations: Ocular lymphoma may indicate systemic lymphoproliferative disorder requiring staging; tuberculosis or fungal infection confirmation necessitates evaluation for pulmonary/systemic involvement; metastatic tumors to eye indicate advanced systemic malignancy; AIDS-related opportunistic infections with CD4 count assessment; diagnosis of syndromic conditions with ocular involvement.
  • Follow-up Tests
    • Tests for Confirmed Malignancy: Molecular/genetic testing (FISH, chromosomal analysis, gene mutations); flow cytometry for lymphoma classification; immunophenotyping; staging imaging (CT orbit/brain, PET scan, MRI orbit); systemic imaging for metastatic disease; tumor-associated antigen studies; genetic prognostic factors for risk stratification.
    • Tests for Identified Infection: Culture and sensitivity testing; PCR confirmation for specific organisms; AFB (acid-fast bacilli) smear for tuberculosis; fungal culture and antigen testing; serology (toxoplasmosis, syphilis, tuberculosis); CD4 count for immunocompromised patients; imaging studies to assess systemic involvement; chest X-ray for pulmonary disease.
    • Tests for Inflammatory Diagnosis: ACE level and chest imaging for sarcoidosis; TB testing (Mantoux, IGRA) for tuberculosis; autoimmune serologies; chest CT/imaging; systematic evaluation for systemic disease; repeat imaging to assess treatment response; inflammatory markers (ESR, CRP).
    • Complementary Imaging Studies: MRI of orbit/brain for better soft tissue delineation; High-resolution CT orbit for bony involvement; Ultrasound B-scan for posterior segment assessment; OCT (optical coherence tomography) for structural evaluation; Fundus photography for documentation; Angiography (fluorescein, indocyanine green) for vascular involvement.
    • Repeat Biopsy Indications: Inconclusive initial pathology; recurrent or progressive disease after treatment; suspected malignancy transformation in previously benign lesions; inadequate initial tissue sampling; different clinical presentation not explained by initial biopsy; monitoring for malignant transformation in dysplastic lesions.
    • Monitoring Frequency: Malignancy: every 3-6 months initially, then annually for years 1-5, then surveillance indefinitely; Inflammatory conditions: initially every 1-4 weeks, then monthly, then quarterly based on response; Infectious disease: depends on organism and immunocompetence status (may require frequent monitoring in AIDS); Dysplastic lesions: every 3-6 months; Benign findings: annual surveillance or symptom-based follow-up.
  • Fasting Required?
    • Fasting Requirement: YES - Fasting is required if general anesthesia will be used; NO - Fasting not required if local anesthesia only is planned.
    • Fasting Duration (if General Anesthesia): NPO (nothing by mouth) for 6-8 hours prior to procedure; typically midnight prior to morning procedure or 6 hours prior to afternoon procedure; clear liquids may be allowed up to 2 hours before procedure (verify with anesthesiologist).
    • Medication Management: Continue essential cardiac and seizure medications with small sip of water; hold anticoagulants (warfarin, apixaban, rivaroxaban) for 3-5 days prior or as directed by physician; hold aspirin/NSAIDs for 5-7 days if possible to reduce bleeding risk; continue diabetes medications as directed; hold diuretics on day of procedure; withhold eye drops on morning of procedure; verify all medication instructions with surgical team.
    • Special Preparation Instructions: Arrange for responsible adult transportation (procedure requires sedation/anesthesia); wear comfortable, loose-fitting clothing; remove all jewelry, contact lenses, and prosthetic devices; informed consent documentation; baseline visual acuity and photography; pre-operative labs if general anesthesia (CBC, metabolic panel, coagulation studies); EKG if cardiac history; communicate allergies (especially iodine, latex) to medical team; arrange time off work for recovery period (typically 24-48 hours).
    • Local Anesthesia Considerations: If local anesthesia only is used, fasting not required; patient may eat light breakfast up to 2 hours before procedure; take regular medications with water as usual; arrive 30-45 minutes before scheduled time for pre-operative preparation; pupil dilation drops may be instilled (verify if needed for specific biopsy location).

How our test process works!

customers
customers